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Gene-associated with retinoid-interferon-induced mortality 19 (GRIM-19) targets
multiple signaling pathways involved in cell death and growth. However, the role of
GRIM-19 in the pathogenesis of hepatitis virus infections remains unexplored. Here,
we investigated the restrictive effects of GRIM-19 on the replication of hepatitis C virus
(HCV). We found that GRIM-19 protein levels were reduced in HCV-infected Huh7 cells
and Huh7 cells harboring HCV replicons. Moreover, ectopically expressed GRIM-19
caused a reduction in both intracellular viral RNA levels and secreted viruses in HCVcc-
infected cell cultures. The restrictive effect on HCV replication was restored by treatment
with siRNA against GRIM-19. Interestingly, GRIM-19 overexpression did not alter the
level of phosphorylated STAT3 or its subcellular distribution. Strikingly, forced expression
of GRIM-19 attenuated an increase in intracellular lipid droplets after oleic acid (OA)
treatment or HCVcc infection. GRIM-19 overexpression abrogated fatty acid-induced
upregulation of sterol regulatory element-binding transcription factor-1 (SREBP-1c),
resulting in attenuated expression of its target genes such as fatty acid synthase (FAS)
and acetyl CoA carboxylase (ACC). Treatment with OA or overexpression of SREBP-1c
in GRIM-19-expressing, HCVcc-infected cells restored HCV replication. Our results
suggest that GRIM-19 interferes with HCV replication by attenuating intracellular lipid
accumulation and therefore is an anti-viral host factor that could be a promising target
for HCV treatment.
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INTRODUCTION
After entry into hepatocytes, hepatitis C virus (HCV) becomes uncoated, and the viral genome is
translated into a single polyprotein that is co- and post-translationally processed into structural and
non-structural proteins (Gale and Foy, 2005; Lindenbach and Rice, 2005). The HCV non-structural
proteins, such as NS3 helicase, NS5A, and NS5B RNA-dependent RNA polymerase, assemble as a
replicase complex (RC) that is associated with lipid-rich membrane structures (Aizaki et al., 2004;
Lindenbach and Rice, 2005). The newly synthesized viral genomes are packaged into viral particles
by the structural proteins, including core, E1, and E2. It has been reported that lipid droplets (LDs)
are important organelles for the viral packing step in HCV production (Miyanari et al., 2007).
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Moreover, newly assembled HCV particles are observed in
close proximity to LDs, indicating that some steps of virus
assembly occur near LDs (Miyanari et al., 2007). The resulting
virus is released from the hepatocyte in association with host
lipoproteins, and therefore, in the blood, HCV is present as
a lipoprotein-coated virus (Meredith et al., 2012). Host lipid
architectures and molecules involved in lipid metabolism are
closely associated with the HCV lifecycle (Suzuki, 2012). Many
studies have shown that lots of host factors participate in HCV
infection and play important roles in efficient viral replication
and propagation (Li et al., 2009). One such host factor is
signal transducer and activator of transcription 3 (STAT3)
(McCartney et al., 2013; Kong et al., 2016; Vallianou et al.,
2016). It was reported that HCV core interacts with and
activates STAT3. The interaction induces expression of STAT3-
dependent genes, such as Bcl-XL and cyclin-D1, resulting in
cellular transformation (Yoshida et al., 2002). Another study
has shown that STAT3 enhances HCV replication through
positive regulation of microtubule dynamics (McCartney et al.,
2013). More recently, it has been demonstrated that HCV NS4B
induces the production of reactive oxygen species (ROS) via
the endoplasmic reticulum overload response (EOR)-mediated
cancer-related STAT3 pathway (Kong et al., 2016). Furthermore,
the roles of cellular regulators of STAT3 such as protein
inhibitor of activated STAT (PIAS) and suppressor of cytokine
signaling (SOCS3) have been investigated in the context of HCV
pathogenesis (El-Saadany et al., 2013; Li Q. et al., 2014; Xu et al.,
2014; Aslam et al., 2016; Zhao et al., 2016). However, the function
of gene-associated with retinoid-interferon-induced mortality 19
(GRIM-19), which is another cellular inhibitor of STAT3, remains
largely unexplored in HCV infection.
GRIM-19 was identified as an interferon (IFN)-β- and
retinoic acid (RA)-induced gene with pro-apoptotic properties
in breast cancer cell lines (Angell et al., 2000). Studies
have demonstrated that GRIM-19 targets multiple signaling
pathways and plays a critical role in controlling cell death and
growth. Overexpression of GRIM-19 induces cell death, and its
suppression or inactivation promotes cell growth (Moreira et al.,
2011). Regarding the role of GRIM-19 in cancer development,
GRIM-19 expression was severely downregulated in a number of
primary renal cell carcinomas (Alchanati et al., 2006), as well as
in hepatocellular carcinoma (Liu et al., 2014) and oral squamous
cell carcinoma (Li M. et al., 2014). Accordingly, upregulation
of GRIM-19 can suppress the growth of specific cancers (Li M.
et al., 2014; Liu et al., 2014). These tumor-suppressive activities
of GRIM-19 may be attributed to its inhibitory role in the
function of STAT3. GRIM-19 was shown to suppress STAT3-
induced gene expression via direct interaction with the trans-
activation domain (TAD) of STAT3 (Nallar et al., 2008). In this
way, binding of GRIM-19 to STAT3 induces changes in the
intracellular distribution of STAT3 and renders cells sensitive to
cell death (Shulga and Pastorino, 2012).
Interestingly, the function of GRIM-19 was reported to be
impeded by viral factors of oncogenic viruses (Kalvakolanu
et al., 2010). The viral interferon regulatory factors (vIRFs)
from human herpesvirus-8 (HHV-8), implicated in cellular
transformation, bind to GRIM-19 and block its ability to induce
apoptosis (Seo et al., 2002). Similarly, a non-coding 2.7-kb viral
RNA (β2.7) produced by human cytomegalovirus (CMV) enters
mitochondria and locks GRIM-19 into Complex-I, rendering it
incapable of triggering apoptosis (Reeves et al., 2007).
In this study, we investigated the role of GRIM-19 as a
host factor restricting HCV infection. We observed that HCV
infection downregulates GRIM-19 at the post-transcriptional
level and that GRIM-19 overexpression interferes with HCV
replication. Regarding the mechanism for these effects, we found
that GRIM-19 decreases intracellular lipid accumulation by
regulating the expression of the sterol regulatory element-binding
transcription factor-1 (SREBP-1c) gene and its downstream
genes. These results suggest that GRIM-19 may be an anti-viral
host factor that could be exploited for the development of novel
antiviral agents.
MATERIALS AND METHODS
Antibodies and Reagents
Mouse monoclonal anti-GRIM-19 antibody was purchased
from Abcam (Cambridge, MA, USA). Mouse monoclonal
anti-β-actin and mouse monoclonal anti-flag antibodies were
obtained from Sigma–Aldrich (St. Louis, MO, USA). Mouse
monoclonal anti-HCV core antibody was purchased from
Thermo Scientific (Rockford, IL, USA). Mouse monoclonal anti-
HCV NS5A antibody was obtained from Virogen (Watertown,
MA, USA). Polyclonal antibodies specific to phospho-STAT3,
STAT3 (Ser-705), and acetyl CoA carboxylase (ACC) were
purchased from Cell Signaling Technology, Inc. (Danvers, MA,
USA). Horseradish peroxidase (HRP)-conjugated anti-mouse,
anti-rabbit immunoglobulin G (IgG), mouse monoclonal anti-
SREBP-1c, mouse monoclonal anti-fatty acid synthase (FAS), and
goat polyclonal anti-stearoyl CoA desaturase (SCD) antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Scrambled siRNA and siRNA targeting GRIM-19 were
obtained from Santa Cruz Biotechnology.
Clinical Materials and Ethics Statement
Four liver tissues from patients with chronic HCV infection were
obtained during surgical procedures such as cholecystectomy,
adrenalectomy, or partial liver resection for intrahepatic duct
stones (Seoul St. Mary’s Hospital, Seoul, South Korea). Three
out of four patients had cirrhotic liver, and the other patient
had chronic hepatitis without cirrhosis. None of them had
history of anti-viral treatment. In addition, four liver tissues
without viral hepatitis were also obtained during surgical
procedures, and they were described in the previous report
(Sung et al., 2015). The study conformed to the current ethical
principles of the Declaration of Helsinki and was approved
by the Institutional Review Board of both Seoul St. Mary’s
Hospital and Daejeon St. Mary’s Hospital at the Catholic
University of Korea. All patients who provided their tissues
completed written informed consents before inclusion in the
study. Additionally, their personal identifying information was
restricted for analysis purposes and is not available to the
public.
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Cell Culture
Huh7 cells were kindly provided by Dr. Jane C. Moores
(The Regent of the University of California, Oakland, CA,
USA). Dr. Francis Chisari (The Scripps Research Institute, CA)
generously provided Huh7.5.1 cells. The cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(FBS), 1% antibiotics (100 µg/mL of penicillin, 0.25 µg/mL of
streptomycin), and 10 µM HEPES in a humidified incubator at
37◦C in 5% CO2.
HCVcc Preparation and Infection
Full-length, infectious HCV RNA of the genotype 2a HCV clone
JFH1 was prepared by in vitro transcription using a MEGAscript
T7 kit (Ambion) and electroporated into Huh7 cells to obtain cell
culture-derived HCV (HCVcc) as previously described (Wakita
et al., 2005). Huh7 cells were infected with HCVcc at a multiplicity
of infection (MOI) of 0.3 by adsorption for 6 h with periodic
rocking and then maintained in complete DMEM as previously
described (Sun et al., 2012).
HCV Replicon Systems
An HCV subgenomic replicon (SGR) construct (pSGR-JFH1)
and an HCV full-genomic replicon (FGR) construct (pFGR-
JFH1) were kindly provided by Dr. Takaji Wakita (National
Institute of Infectious Diseases, Tokyo, Japan). The constructs
were linearized and then used for in vitro transcription as
described above. Huh7 cell-derived cell lines containing the HCV
SGR or HCV FGR were established by transfection of in vitro-
transcribed HCV subgenomic or HCV full-genomic RNA,
followed by selection with 500 µg/mL G418 sulfate as previously
described (Date et al., 2007). The selected cell lines were
maintained in complete DMEM containing 500 µg/mL G418
sulfate. HCV genotype-3 replicon cells derived from Huh7.5.1
cells were kindly provided from Dr. Sung Key Jang (Pohang
University of Science and Technology, Pohang, Kyungbuk, South
Korea).
Western Blot Analysis
Huh7 cells and Huh7 cells in which HCV replication occurs
were lysed with PRO-PREP Protein Extraction Solution (iNtRon
BIOTECHNOLGY) containing protease inhibitors. Total protein
content was determined using a Bradford protein assay kit (Bio-
Rad Laboratories, Hercules, CA, USA). Thirty micrograms of
the extracted proteins were subjected to western blot analysis.
The analysis was performed as previously described (Choi et al.,
2015). The density of each band was analyzed using the Multi
Gauge V3.0 program (Fujifilm, Tokyo, Japan).
Plasmids
pcDNA3_GRIM-19 was constructed to overexpress
GRIM-19. The GRIM-19 gene was amplified by PCR with
GRIM-19-specific primers (GRIM-19-HindIII-F, 5′-CCC
AAGCTTACCATGGCGGCGTCAAAGGTG-3′ and GRIM-19-
EcoR I-R, 5′-CGGAATTCTTACGTGTACCACATGAAGCCG-
3′) using cDNAs that were reverse transcribed using random
primers from RNA extracted from Huh7 cells. The PCR products
were cut with HindIII and EcoRI and inserted into a pcDNA3
vector (Invitrogen) in frame. To evaluate the efficiency of
transfection with foreign gene-encoding plasmid in Huh7 cells,
pEGFP-C1_GRIM-19 was constructed. The GRIM-19 gene was
amplified by PCR with GRIM-19-specific primers (GRIM-19-
BglII, GGAAGATCTATGGCGGCGTCAAAGGTGAAG and
GRIM-19-EcoRI-R) as described above. The PCR products were
cut with BglII and EcoRI and inserted into the pEGFP-C1 vector
(Clontech Laboratories, Mountain View, CA, USA) in frame.
pcDNA3_EGFP was kindly provided by Dr. Sean B. Lee (Tulane
University, New Orleans, LA, USA). pcDNA3.1-2xflag-SREBP1c
was purchased from Addgene (Cambridge, MA, USA).
Transient Transfection
To investigate the effects of GRIM-19 on HCV replication and
lipogenesis, Huh7 cells or Huh7 cells in which HCV replication
occurs were transfected with various plasmids as described above
using FUGENE HD (Promega, Madison, WI, USA) according to
the manufacturer’s protocol.
Real-time Quantitative Reverse
Transcription-PCR (rqRT-PCR)
The levels of HCV RNA in Huh7 cells infected with HCVcc
were evaluated to verify the anti-HCV effects of GRIM-19.
Total RNA was extracted with TRIzol reagent (Invitrogen) and
purified according to the manufacturer’s recommendations.
cDNA was synthesized from 2 µg of total RNA with
primers specific for the HCV 5′UTR (HCV-5′UTR-R, 5′-
ACCACAAGGCCTTTCGCAACCCAACGCTAC-3′) using
ImProm-II reverse transcriptase (Promega). cDNA was then
subjected to real-time, quantitative RT-PCR (rqRT-PCR) using
primer pairs and a TaqMan probe targeting a region within
the HCV 5′UTR as previously described (Kim et al., 2009).
rqRT-PCR was performed using a LightCycler 480 Probes Master
kit (Roche Applied Science) and a LightCycler 480 system (Roche
Applied Science) according to the manufacturer’s instructions.
Endogenous mRNA levels of GRIM-19 and genes involved
in lipid metabolism were also assessed using the LightCycler
480 Probes Master kit and the LightCycler 480 system with
gene-specific primers and fluorescent probes recommended
by Roche Universal Probe Library Design Center. The thermal
conditions were designed using the Roche Universal Probe
Library’s thermocycling conditions following the manufacturer’s
instructions. Human β-actin was used as a reference gene. All
fluorescence data were analyzed using LightCycler 4.0 software
(Roche Applied Science), and Ct results were exported to Excel
spreadsheets. The comparative Ct method was used for relative
quantification and normalization.
Dual-luciferase Assay
Changes in HCV-internal ribosome entry site (IRES) activity
were confirmed by a dual-luciferase assay. A dual-luciferase
reporter construct was kindly provided by Dr. Jong-Won Oh
(Yonsei University, Seoul, South Korea). It contains a CMV
promoter-controlled Renilla luciferase reporter gene followed
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by the HCV IRES-controlled firefly luciferase reporter gene.
Huh7 cells infected with HCVcc were cotransfected with the
dual-luciferase reporter construct and pcDNA3_GRIM-19 using
fuGENE HD. At 48 h post-transfection, dual-luciferase assays
were performed with a Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions.
Subcellular Fractionation
Huh7 cells infected with HCVcc were transfected with pcDNA3
or pcDNA3_GRIM-19. After 48 h, the cells were subjected to
subcellular fractionation into nuclear and cytoplasmic fractions
using an NE-PER kit (Pierce, Rockford, IL, USA) according to
the manufacturer’s recommendations.
Reverse Transcription-polymerase Chain
Reaction (RT-PCR)
The mRNA levels of bcl2 and mmp2 were evaluated using
RT-PCR. Total RNA extraction and cDNA synthesis using
random primers were performed as described above. Gene
amplification was performed with GoTaq Polymerase
(Promega) and specific primer pairs for bcl2 (bcl2-F, 5′-
TCCCTCGCTGCACAAATACTC-3′, and bcl2-R, 5′-TTCTG
CCCCTGCCAAATCT-3′) and mmp2 (mmp2-F, 5′-CCACTGCC
TTCGATACAC-3′, and mmp2-R, 5′-GAGCCACTCTCT
GGAATCTTAAA-3′). The PCR program ran as follows: 10 min
at 94◦C; 30 cycles of 94◦C for 30 s, 55◦C for 30 s, and 72◦C for
45 s; followed by a final 10 min incubation at 72◦C. The amplified
products were separated on 1.5% agarose gels containing
0.5 mg/mL ethidium bromide. The nucleic acids were visualized
under UV light using a Gel-Doc CQ system (Bio-Rad, Vienna,
Austria), and the band densities of each gene were analyzed using
the Multi Gauge V3.0 program with β-actin serving as a loading
control.
Apoptosis Assays
Apoptosis was detected with Annexin V/propidium iodide
(PI) staining (BD BioSciences) according to the manufacturer’s
instructions. In total, 10, 000 cells were counted by flow
cytometry using a fluorescence-activated cell sorter (FACS,
Becton-Dickinson, San Jose, CA, USA). The resulting data were
analyzed using Summit 5.2 software (Beckman Coulter Inc.,
Miami, FL, USA).
Intracellular Lipid Droplet Quantification
Huh7 cells and HCVcc-infected Huh7 cells were treated with
100 µM oleic acid (OA) in serum-free DMEM containing
1% BSA at 24 h post-transfection with pcDNA3_GRIM-19
or pEGFP-C1_GRIM-19. Twenty-four hours later, the cells
were subjected to Nile Red staining to evaluate the changes
in intracellular lipid content. The cells were washed with
ice-cold phosphate-buffered saline (PBS) and fixed with 4%
paraformaldehyde for 5 min at room temperature. After being
washed with PBS again, the cells were stained with Nile
Red (0.5 µg/mL) and 4′,6-diamidino-2-phenyl-indole (DAPI,
1 µg/mL) (Sigma–Aldrich). After staining, intracellular LDs were
quantified by measuring density of fluorescence with a microplate
reader (Molecular Devices, Sunnyvale, CA, USA), and the results
were normalized to the cellular DAPI content (Hur et al., 2012).
The distribution of lipid in cells was observed under an LSM 510
inverted laser-scanning confocal microscope (Carl Zeiss, Jena,
Germany).
Immunofluorescence Staining
Huh7 cells and HCVcc-infected Huh7 cells were fixed with
4% paraformaldehyde for 30 min, and permeabilized with PBS
containing 0.2% Triton X-100 for 30 min at room temperature.
After washing three times with PBS, the cells were treated with
a blocking solution (PBS containing 1% BSA, 0.1% gelatin, and
5% goat serum) for 30 min at room temperature, incubated with
primary antibody overnight at 4◦C, and washed five times with
PBS containing 1% BSA and 0.1% gelatin. The cells were further
incubated with secondary antibodies (Molecular Probes, Eugene,
OR, USA) for 2 h and washed five times with PBS. Nuclei were
visualized using (DAPI) in PBS for 10 min. Stained slides were
observed under an LSM 510 inverted laser-scanning confocal
microscope (Carl Zeiss).
Statistical Analysis
All data are representative of a minimum of three independent
experiments. The data are expressed as the mean ± SD or
±SEM. For comparison of multiple groups, one-way analysis of
variance (ANOVA) with Tukey’s post hoc test was used to define
statistically significant differences among groups. For statistical
comparisons between two groups, Student’s t-test was used. The
statistical significance of differences between groups is expressed
by an asterisk (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
RESULTS
GRIM-19 Protein Levels Are
Downregulated in HCV-infected Cells
First, we examined the expression of GRIM-19 protein in Huh7
cells infected with genotype 2a HCVcc. As shown in Figure 1A,
GRIM-19 expression decreased in Huh7 cells infected with
HCVcc. On the 3rd day of HCV infection, protein level of
GRIM-19 was downregulated by approximately 20%. Moreover,
GRIM-19 expression was decreased by approximately 50% on
the 12th day of HCV infection. To confirm the downregulation
of GRIM-19 in HCV-replicating cells, we assessed GRIM-19
expression in genotype 2a HCV SGR cells and FGR cells. In these
cells, the GRIM-19 protein level was lower than that in Huh7
control cells (Figure 1B). Furthermore, in the genotype 3 HCV
FGR cell line derived from Huh7.5.1 cells, the expression level
of GRIM-19 was lower compared to that in parental Huh7.5.1
cells (Figure 1C). Interestingly, GRIM-19 mRNA levels were not
altered in the cells with active HCV replication (Figure 1D).
Next, we determined the protein levels of GRIM-19 in liver
tissues from patients with chronic HCV infection. Compared
to the liver tissues without viral hepatitis, HCV-infected livers
expressed markedly lower levels of GRIM-19 protein (Figure 1E).
These results suggest that HCV infection causes downregulation
of GRIM-19 at the post-transcriptional level.
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FIGURE 1 | Hepatitis C virus (HCV) infection and viral replication
reduced GRIM-19 expression. (A,B) Protein levels of GRIM-19 were
evaluated using western blot analysis in Huh7 cells infected with HCVcc at
days 3, 6, 9, and 12 post-infection (A), FGR cells (B), and SGR cells (B). The
relative protein expression was normalized to β-actin as a reference. (C) The
endogenous GRIM-19 level was assessed by western blot analysis in
Huh7.5.1 cells or Huh7.5.1-derived HCV genotype 3 full genomic replicon
cells. The relative protein expression was normalized to β-actin as a reference.
(D) Relative levels of endogenous GRIM-19 mRNA in SGR cells, FGR cells,
and HCVcc-infected Huh7 cells compared to that in Huh7 cells. β-actin was
used as a reference gene. (E) Protein levels of GRIM-19 in liver tissues from
patients with chronic liver diseases (CLD) caused by persistent HCV infection
(n = 4) were analyzed by western blot analysis. Tissue lysates from liver
without viral hepatitis were used as a control (normal; n = 4). β-actin was used
as a loading control. The values of the GRIM-19 protein levels were expressed
relative to the level in control tissues (right). All data represent the mean ± SEM
(n = 3). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to control.
Ectopically Expressed GRIM-19 Reduces
HCV RNA Replication
To investigate the roles of GRIM-19 in the HCV viral life
cycle, we overexpressed GRIM-19 in HCVcc-infected or HCV
replicon cells (Figure 2). GRIM-19 was ectopically expressed
in the cells via transient transfection as described in section
“Materials and Methods”. Before evaluation of the effect of
GRIM-19 overexpression on HCV replication, the transfection
efficiency of Huh7 cells was checked using flow cytometry after
transfection with enhanced green fluorescent protein (EGFP)-
fused GRIM-19-encoding plasmids. As shown in Figure 2B,
GFP fluorescence was detected in a high percentage of
Huh7 cells transfected with EGFP-fused GRIM-19-encoding
plasmids, even though the density of fluorescence among
the cells was different. In the same transient transfection
conditions, GRIM-19 was overexpressed in HCVcc-infected
Huh7 cells. When Huh7 cells were infected with HCVcc
at an MOI of 0.3, the level of intracellular HCV RNA
was gradually increased until the 12th day after infection
(Figure 2G). The level of intracellular HCV RNA on the
15th day was comparable to that on the 12th day (data
not shown). These results indicate that the ratio of Huh7
cells infected with HCVcc to uninfected cells reached the
highest level on approximately the 12th day after HCVcc
infection at an MOI of 0.3. Therefore, to examine the
effect of GRIM-19 overexpression on HCV replication, Huh7
cells infected with HCVcc were seeded on the 9th day
post-infection, and the next day, the cells were transfected
with GRIM-19 encoding plasmid. After 48 h, the levels
of intracellular HCV RNA and protein were evaluated. As
shown in Figure 2C, GRIM-19 overexpression resulted in
an approximately 50% decrease in the levels of intracellular
HCV RNA in Huh7 cells infected with HCVcc. Moreover,
transient transfection with GRIM-19-encoding plasmid also
reduced the protein level of HCV NS5A (Figure 2C, right).
Ectopically expressed EGFP did not have an effect on the
levels of either intracellular HCV RNA or HCV NS5A
protein (Figure 2C). Interestingly, GRIM-19 transfected, HCVcc-
infected cells secreted a much lower number of viral particles
(Figure 2D, left). When Huh7 cells were re-infected with
culture supernatants obtained from HCVcc-infected, GRIM-19-
transfected cells, the levels of intracellular HCV RNA were
lower (Figure 2D, right). Anti-HCV activity of GRIM-19 was
also confirmed in FGR cells and SGR cells. As expected,
GRIM-19 overexpression reduced the HCV RNA level to
less than 50% in FGR cells and SGR cells (Figures 2E
right, F). Additionally, ectopically expressed GRIM-19 reduced
the protein level of HCV core in FGR cells (Figure 2E,
right). Moreover, in the cells, EGFP overexpression did not
have an effect on the levels of either intracellular HCV RNA
or HCV core protein (Figure 2E). Furthermore, repeated
transfection of Huh7 cells infected with HCVcc with GRIM-
19 encoding plasmid resulted in additive inhibitory effects
on HCV RNA replication (Figure 2G). In the first round
of transfection with GRIM-19, the level of HCV RNA
was 59% that of pcDNA3-transfected cells. After the fourth
round of GRIM-19 transfection, the level of HCV RNA
was 19% that of vehicle-transfected, HCVcc-infected Huh-
7 cells. To confirm the suppressive function of GRIM-19
on HCV replication, we examined whether the inhibitory
effect of GRIM-19 on HCV replication could be abolished
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FIGURE 2 | Anti-HCV activity of ectopically expressed GRIM-19. (A) Overexpression of GRIM-19 was induced by transfection with pcDNA3_GRIM-19 in Huh7
cells. At 48 h post-transfection, GRIM-19 overexpression was detected by western blot analysis. (B) Huh7 cells were transfected with pEGFP-C1 or
pEGFP-C1-GRIM-19. After 48 h, the cells were subjected to flow cytometry to evaluate the transfection efficiency. (C) HCVcc-infected Huh7 cells at day 9
post-infection were transfected with pcDNA3, pcDNA3_GRIM-19 or pcDNA3_EGFP. After 48 h, the intracellular levels of HCV RNA were evaluated by rqRT PCR
(left), and the protein level of HCV NS5A was detected by western blot analysis (right). The values of the HCV RNA levels were expressed relative to the level in cells
transfected with pcDNA3. (D) At day 9 post-infection, HCVcc-infected Huh7 cells were transfected with pcDNA3 or pcDNA3_GRIM-19. After 48 h, the culture media
was used to evaluate the extracellular level of HCV RNA (left) as well as for re-infection. After another 48 h, the HCV RNA levels in re-infected Huh7 cells were
evaluated by rqRT PCR. (E) Levels of HCV RNA and HCV core protein in FGR cells were analyzed after transfection with pcDNA3, pcDNA3_GRIM-19 or
pcDNA3_EGFP as in (C). (F) The values of the HCV RNA levels are analyzed in SGR cells transfected with pcDNA3 or pcDNA3_GRIM-19 as in (C). (G) To examine
the inhibitory effect of repeated transfection with pcDNA3_GRIM-19, Huh7 cells were infected with HCVcc at an MOI of 0.3. After 24 h, cells were transfected with
pcDNA3 or pcDNA3_GRIM-19. The cells were maintained at 3-day intervals and transfected with pcDNA3 or pcDNA3_GRIM-19 repeatedly. At 3, 6, 9, and 12 days
post-infection, cells were harvested, and HCV RNA levels were evaluated. (H) At day 9 post-infection, HCVcc-infected Huh7 cells were transfected with pcDNA3 or
pcDNA3_GRIM-19. After 24 h, the cells were transfected with scrambled siRNA or GRIM-19-siRNA. Changes in GRIM-19 levels were assessed by western blot
analysis 48 h post-transfection with siRNAs (bottom). In addition, HCV RNA levels were evaluated by rqRT-PCR (top). (I) HCV-IRES activity in Huh7 transfected with
pcDNA3 or pcDNA3_GRIM-19. The data represent the means ± SEM (n = 3). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to control.
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FIGURE 3 | GRIM-19 overexpression did not alter STAT3 transcriptional activity. (A) The expression and phosphorylation of STAT3 after transfection with
pcDNA3 or pcDNA3_GRIM-19 were evaluated by western blot analysis. β-actin was used as an internal control for loading. (B) To evaluate subcellular localization of
phospho-STAT3, STAT3, and GRIM-19, HCVcc-infected Huh7 cells were transfected with pEGFP-C1 or pEGFP-C1_GRIM-19. After 48 h, the cells were subjected
to subcellular fractionation followed by western blot analysis. PARP and SOD1 were used as markers for the nucleus and cytosol. (C) The mRNA levels of bcl2 and
mmp2 were assessed by RT-PCR with a gene-specific primer set. The mRNA expression was normalized to β-actin as a reference and expressed relative to the
density of Huh7 cells. Values represent means ± SD. (D) Examination of the induction of apoptosis by overexpression of GRIM-19 in Huh7 cells or FGR cells. The
cells were transfected with pcDNA3 or pcDNA3_GRIM-19. After 48 h, apoptosis was determined by a Annexin V/PI staining.
by siRNA against GRIM-19. In HCVcc-infected, GRIM-
19-overexpressing Huh7 cells, transfection with GRIM-19
siRNA abrogated the suppressive effect of GRIM-19
on HCV replication (Figure 2H). Collectively, these
results suggest that GRIM-19 overexpression inhibits
HCV.
Viral Internal Ribosome Entry Site
(IRES)-Mediated Translation of the HCV
Genome Is Not Altered by GRIM-19
Next, we investigated whether GRIM-19 overexpression had an
effect on HCV-IRES activity. Huh7 cells were transfected
with GRIM-19-encoding plasmid and a dual-luciferase
reporter construct, allowing cap-dependent expression of
Renilla luciferase and HCV IRES-dependent translation of
firefly luciferase. As shown in Figure 2I, forced expression
of GRIM-19 did not alter HCV IRES activity. These results
suggest that the suppressive effect of GRIM-19 on HCV
RNA replication is not caused by alteration of HCV-IRES
activity.
GRIM-19 Overexpression Does Not Alter
the Subcellular Localization or the
Transcriptional Activity of
Phosphorylated STAT3 in
HCVcc-infected Cells
As described above, one of the host factors that interact with
HCV proteins is STAT3. Because GRIM-19 is known to interact
with phosphorylated STAT3 and transport it out of the nucleus
(Shulga and Pastorino, 2012), we investigated whether GRIM-19
overexpression has an effect on STAT3 activation in HCVcc-
infected Huh7 cells. First, we aimed to confirm the amount
and subcellular localization of phosphorylated STAT3 in Huh7
cells infected with HCVcc after transfection with a GRIM-19-
encoding plasmid. The level of phosphorylated STAT3 increased
after infection with HCVcc in Huh7 cells (Figure 3A); however,
overexpression of GRIM-19 did not reduce the increased
phosphorylation of STAT3 (Figure 3A). Furthermore, GRIM-19
overexpression did not induce translocation of phosphorylated
STAT3 (Figure 3B). Follow-up experiments showed that the
expression levels of bcl2 and mmp2, which are induced
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FIGURE 4 | GRIM-19 overexpression inhibited lipid accumulation. (A) Huh7 cells were transfected with pcDNA3 or pcDNA3_GRIM-19. After 24 h, cells were
treated with 100 µM OA. After an additional 24 h, intracellular lipid accumulation was visualized by Nile Red staining and observed under a confocal microscope
(left). Red, lipid droplets (LDs); blue, DAPI; original magnification 200×. Fluorescence densities of Nile Red were quantified using a microplate reader and normalized
to the cellular DAPI content. The values of intracellular lipid level were expressed relative to the level in the cells transfected with pcDNA3 and without OA treatment
(right). The data represent the mean ± SEM (n = 3). ∗∗P < 0.01, ∗∗∗P < 0.001 compared to control. (B) Huh7 cells were transfected with pEGFP-C1 or
pEGFP-C1-GRIM-19. After 24 h, cells were treated with 100 µM OA. After an additional 24 h, intracellular lipid accumulation was assessed by Nile Red staining.
Red, LDs; Green, EGFP or EGFP-fused GRIM-19; blue, DAPI; original magnification 800×. (C) HCV core was immunostained in Huh7 cells infected with HCVcc at
day 9 post-infection. Red, HCV core; blue, DAPI; original magnification 400×. (D) Changes of intracellular lipid accumulation by GRIM-19 overexpression was
assessed in Huh7 cells infected with HCVcc at day 9 post-infection as in (A). (E) Smaller size and number of LDs in GRIM-19 overexpressing cells were visualized in
HCVcc infected Huh7 cells as in (B).
by transcriptional activation of STAT3, were not altered by
overexpression of GRIM-19 (Figure 3C). Furthermore, GRIM19
overexpression did not induce sufficient apoptosis to show anti-
HCV activity in HCV-replicating Huh7 cells (Figure 3D). These
results suggest that the inhibitory effect of GRIM-19 on HCV
replication is not associated with altered STAT3 activation in
HCV-infected cells.
GRIM-19 Attenuates Intracellular Lipid
Accumulation
The level of HCV RNA was significantly downregulated by
transfection with GRIM-19-encoding plasmids in SGR cells
(Figure 2F). This suggests that the anti-viral function of
GRIM-19 may be closely associated with HCV replication
or viral RC formation. As shown in Figure 2I, GRIM-19
overexpression does not restrict viral translation. In addition,
the dependence of HCV replication and viral RC formation
on intracellular lipid accumulation is well known (Kapadia and
Chisari, 2005; Mankouri et al., 2010; Pisonero-Vaquero et al.,
2014; Akil et al., 2016). Therefore, we further investigated
whether GRIM-19 overexpression affects intracellular lipid
accumulation. Huh7 cells and HCVcc-infected Huh7 cells were
transfected with GRIM-19-encoding plasmids. In both types
of cells, treatment with OA increased intracellular lipid levels
by up to approximately 140% (Figures 4A,D). However, in
cells overexpressing GRIM-19, the levels of intracellular lipid
accumulation after treatment with OA were comparable to that
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of untreated cells (Figures 4A,D). Moreover, the number and size
of LDs after OA treatment were smaller in the cells transfected
with EGFP-fused GRIM-19-encoding plasmids compared to that
in untransfected cells (Figures 4B,E). Furthermore, as shown in
Figure 4C, HCV core protein was detected in most Huh7 cells
infected with HCVcc on the 9th day post-infection, and in the
cells, the amount of intracellular lipids increased without OA
treatment, as previously reported (Figure 4D) (McRae et al.,
2015; Akil et al., 2016). Additionally, overexpression of GRIM-19
significantly reduced the level of intracellular lipid accumulation
caused by HCV infection (Figure 4D). These results may indicate
that GRIM-19 can ameliorate intracellular lipid accumulation in
hepatocytes.
GRIM-19 Overexpression Downregulates
the Expression Levels of SREBP1-c and
Its Target Genes
Next, we investigated the mRNA level of transcription
factors involved in regulating the intracellular lipid level
after transfection with GRIM-19-encoding plasmids. We
examined the expression of the following transcription
factors: (i) SREBP-1c, known to induce de novo lipogenesis
to generate free fatty acid (FFA) (Sanders and Griffin, 2016);
(ii) peroxisome proliferator-activated receptor α (PPARα),
required for mitochondrial, peroxisomal, and microsomal
FFA oxidation (Memon et al., 2000); and (iii) peroxisome
proliferator-activated receptor γ (PPARγ), which is known
to contribute to FFA uptake (Ahmadian et al., 2013). Among
these three transcription factors, only SREBP-1c expression
levels were significantly upregulated in Huh7 cells treated
with 100 µM OA and downregulated by transfection with
GRIM-19-encoding plasmids before OA treatment (Figures 5A
left, C). Interestingly, the mRNA levels of SREBP-1c target
genes involved in triglyceride biosynthesis such as FAS, SCD,
and ACC were upregulated following treatment with OA
and downregulated as a result of GRIM-19 overexpression
induced prior to OA treatment (Figure 5B). Moreover,
increased ACC and FAS protein levels resulting from OA
treatment were downregulated by ectopically expressed GRIM-
19 (Figure 5C). In both FGR cells and Huh7 cells infected
with HCVcc, the expression levels of SREBP-1c, FAS, and ACC
were remarkably downregulated by GRIM-19 overexpression
(Figures 5D,E). Unexpectedly, the protein levels of SCD were
not significantly altered by GRIM-19 overexpression in the
cells (Figures 5C–E). Next, we further determined the effect of
GRIM-19 on the expression levels of other enzymes involved
in lipid metabolism. Interestingly, the expression levels of
diacylglycerol acyltransferase-1 (DGAT-1) and diacylglycerol
acyltransferase-2 (DGAT-2), which catalyze the final step in
triglyceride biosynthesis, were not significantly affected by
GRIM-19 overexpression (Figure 5F). Likewise, microsomal
triglyceride transfer protein (MTP), which is involved in the
assembly/secretion of very low density lipoproteins (VLDL), was
not upregulated by OA treatment even though overexpression
of GRIM-19 decreased the MTP mRNA level (Figure 5F).
Taken together, these results demonstrate that GRIM-19 may
ameliorate intracellular lipid accumulation by regulating the
expression of SREBP-1c and its target genes.
GRIM-19 Restricts HCV Replication
through Downregulation of SREBP-1c
To confirm the suppressive effect of GRIM-19 on intracellular
lipid accumulation, we examined whether the restrictive
effect of GRIM-19 on HCV replication could be abolished
by OA treatment or normalization of SREBP-1c expression.
As shown in Figure 6A, OA treatment in the absence of
GRIM-19 transfection increased the HCV RNA titer in HCVcc-
infected Huh7 cells. Moreover, in HCVcc-infected, GRIM-19-
overexpressing Huh7 cells, downregulation of HCV RNA was
restored by OA treatment (Figure 6A). In the same manner,
SREBP-1c overexpression increased the level of HCV RNA and
abolished the restrictive effect of GRIM-19 on HCV replication
(Figure 6B). These results suggest that the inhibitory effect of
GRIM-19 overexpression on HCV replication is mediated by
downregulation of SREBP-1c.
DISCUSSION
In this study, we uncovered a new biological function of
GRIM-19 in lipid metabolism, as summarized in Figure 7.
HCV replication caused the GRIM19 protein level to decrease.
However, restoration of the downregulated level of GRIM-
19 by transient transfection with a GRIM-19-encoding
plasmid restricted HCV replication. Interestingly, GRIM-19
overexpression downregulated the expression of SREBP-1c and
its target genes, resulting in abrogation of the intracellular lipid
accumulation induced by HCV replication. These results suggest
that GRIM-19 can be thought of as a host factor that restricts
HCV replication.
It is known that HCV exploits host lipid architectures and
molecules involved in lipid metabolism for its efficient replication
and propagation (Miyanari et al., 2007; Negro and Sanyal, 2009;
Syed et al., 2010). For example, HCV genome replication, in
common with other positive-strand RNA viruses, occurs within
a “membranous web” derived from intracellular vesicles (Egger
et al., 2002; Miyanari et al., 2007). Additionally, it has been
reported that LDs act as a platform for HCV replication and
assembly (Miyanari et al., 2007). HCV core protein recruits
HCV RNA, non-structural proteins, and replication complexes
to LD-associated membranes. Thus, this recruitment is critical
for infectious virus particle production (Miyanari et al., 2007).
For these reasons, HCV induces intracellular lipid accumulation
to optimize the cellular environment for persistent infection
(Kapadia and Chisari, 2005; Mankouri et al., 2010; Akil et al.,
2016). As one of the strategies to increase intracellular lipids,
HCV activates SREBPs (Waris et al., 2007; Negro and Sanyal,
2009; Syed et al., 2010). Recent research has demonstrated that
HCV NS4B, NS5A, and core protein may activate SREBP-1c and
its target genes, resulting in enhanced fatty acid biosynthesis
(Park et al., 2009; Syed et al., 2010; Xiang et al., 2010;
Garcia-Mediavilla et al., 2012). Moreover, inhibiting or silencing
SREBP by treatment with 25-hydroxycholesterol inhibits HCV
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FIGURE 5 | Effect of GRIM-19 overexpression on the expression levels of genes involved in lipid metabolism. (A) Examination of the mRNA levels of three
transcription factors that regulate the intracellular lipid level in Huh7 cells treated with OA or transfected with pcDNA3 or pcDNA3_GRIM-19. The mRNA expression
was normalized to β-actin as a reference and the values of mRNA level were expressed relative to the level in cells transfected with pcDNA3 and without OA
treatment. (B) mRNA levels of target genes of SREBP-1c were analyzed as in (A). (C) Protein levels of SREBP-1c and its target genes in Huh7 cells treated as in (A)
were analyzed using western blot analysis. β-actin was used as an internal control for loading. (D,E) Protein levels of SREBP-1c and its target genes after
transfection with pcDNA3 or pcDNA3_GRIM-19 in FGR cells (D) and Huh7 cells infected with HCVcc at day 9 post-infection (E). β-actin was used as an internal
control for loading. (F) mRNA levels of DGAT1, DGAT-2, and MTP were analyzed as in (A). The data represent the mean ± SEM (n = 3). ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001 compared to control.
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FIGURE 6 | Restoration of GRIM-19 inhibition of HCV replication. At day 9 post-infection, HCVcc-infected Huh7 cells were transfected with pcDNA3 or
pcDNA3_GRIM-19. After 24 h, the cells were treated with OA (A) or transfected with SREBP-1c-overexpressing plasmids (B). After an additional 48 h, intracellular
levels of HCV RNA were evaluated by rqRT PCR (top), and the overexpressed protein levels was detected by western blot analysis (bottom). The values of the HCV
RNA levels were expressed relative to the level in cells transfected with pcDNA3. The data represent the mean ± SEM (n = 3). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001
compared to control.
replication (Su et al., 2002; Yang et al., 2008; Li et al., 2013).
In the present study, we showed that GRIM-19 overexpression
impeded the lipid accumulation induced by OA treatment and
HCV infection through downregulation of SREBP-1c expression.
Furthermore, the expression of SREBP-1c target genes, such as
ACC and FAS but not SCD was markedly downregulated by
GRIM-19 overexpression. Luyimbazi et al. (2010) demonstrated
that translation of SCD is regulated by eukaryotic initiation
factor 4E (eIF4E), suggesting that mTOR may regulate SCD
through the mTOR/4E-BP1/eIF4E axis. More recently, it was
reported that eIF4E could be activated in HCV-replicating cells
for efficient viral translation (George et al., 2012; Licursi et al.,
2012; Panda et al., 2014). Based on these reports, we speculate
that eIF4E activation by HCV could be one of the reasons that
mRNA levels of SCD are decreased by GRIM-19 overexpression
but the protein levels of SCD are not affected under the
same conditions. However, future investigations are needed to
understand the exact mechanisms of a sustained level of SCD
protein after transfection with GRIM-19-encoding plasmids.
Despite the fact that SCD expression was not modulated by
GRIM-19 overexpression, these findings suggest that GRIM-
19 may abrogate intracellular lipid accumulation by inhibiting
SREBP-1c activation and that these inhibitory effects could
restrict HCV replication.
Signal transducer and activator of transcription 3, a major
oncogenic transcription factor involved in cancer development
and progression, is regulated by GRIM19 in some tumor cell
lines (Alchanati et al., 2006; Kalakonda et al., 2007), but little
is known regarding their relationships in viral infections. For
this reason, we explored a specific functional link between
FIGURE 7 | A proposed model of the mechanism underlying the
anti-HCV activity of GRIM-19. After HCV infection, lipid biosynthesis is
upregulated via SREBP-1c activation. SREBP-1c is a transcription factor that
enhances the expression of genes involved in fatty acid biosynthesis such as
ACC, FAS, and SCD, causing increased levels of triglycerides that help create
an appropriate microenvironment for persistent HCV infection. Conversely,
GRIM-19 function is downregulated through the reduction of its protein levels
in HCV-replicating cells. However, restoration of GRIM-19 expression can
disrupt this suitable microenvironment by downregulating SREBP-1c
expression.
GRIM19 and STAT3 in HCV infection. However, our results
showed that the inhibitory effect of GRIM-19 on HCV replication
was not associated with altered STAT3 activation in HCV-
infected cells. Moreover, the precise mechanism by which
GRIM-19 downregulates SREBP-1c gene expression remains
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unclear. Hence, further investigation is warranted concerning
the functional links among GRIM-19, STAT3, and SREBP-1c in
HCV infection. Interestingly, a recent study showed that leptin-
induced STAT3 downregulates SREBP-1c expression in hepatic
stellate cells (Zhang et al., 2013). Therefore, it appears that STAT3
activity is not strongly associated with GRIM-19 inhibition of
SREBP-1c expression.
To date, the role of p53 in lipid metabolism is still uncertain;
however, p53 and its target genes may be anti-viral host factors
in HCV pathogenesis because they are also impaired by HCV
infection (Nishimura et al., 2009). Recently, Zhou et al. (2011)
demonstrated that the p53 tumor suppressor was regulated
by GRIM-19 expression. They showed that GRIM-19 helps to
stabilize p53 by interacting with E6 and E6AP proteins and
inducing ubiquitination and degradation of E6AP, resulting in
the promotion of apoptosis in a cervical cancer cell line (Zhou
et al., 2011). In contrast, another study by Ruedo-Rincon et al.
(2015) demonstrated that p53 could decrease SCD expression by
repressing SREBP-1c. Based on these results, we speculate that
p53 is involved in the negative regulation of SREBP-1c expression
by GRIM-19. However, future investigations are needed to
understand the exact mechanisms of the interaction between p53
and GRIM-19 during SREBP1-c expression and lipid metabolism.
CONCLUSION
Our data reveal a previously unknown role of GRIM-19
in lipid metabolism during HCV pathogenesis. GRIM-19
overexpression abrogated intracellular lipid accumulation
through downregulation of SREBP-1c and its target genes,
resulting in restriction of HCV replication. These results provide
valuable information regarding GRIM-19, a host factor involved
in HCV replication. Furthermore, this new knowledge regarding
GRIM-19 may facilitate new strategies against diseases related to
lipid metabolic disorders.
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